KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) FCF Margin (2016 - 2025)

Historic FCF Margin for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q3 2025 value amounting to 9528.46%.

  • CRISPR Therapeutics AG's FCF Margin rose 82675500.0% to 9528.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 790.73%, marking a year-over-year decrease of 6964700.0%. This contributed to the annual value of 387.72% for FY2024, which is 3150300.0% down from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's FCF Margin stood at 9528.46%, which was up 82675500.0% from 12779.93% recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's FCF Margin registered a high of 21633.13% during Q1 2024, and its lowest value of 1991983.33% during Q4 2022.
  • Moreover, its 5-year median value for FCF Margin was 11154.2% (2025), whereas its average is 127852.73%.
  • Its FCF Margin has fluctuated over the past 5 years, first tumbled by 2000000000bps in 2022, then skyrocketed by 2000000000bps in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's FCF Margin (Quarter) stood at 738.2% in 2021, then crashed by -269742bps to 1991983.33% in 2022, then surged by 100bps to 48.12% in 2023, then plummeted by -193bps to 140.89% in 2024, then crashed by -6663bps to 9528.46% in 2025.
  • Its FCF Margin stands at 9528.46% for Q3 2025, versus 12779.93% for Q2 2025 and 6260.46% for Q1 2025.